Oki Y - Search Results

1

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia.

Kantarjian H, Oki Y, Garcia-Manero G, Huang X, O'Brien S, Cortes J, Faderl S, Bueso-Ramos C, Ravandi F, Estrov Z, Ferrajoli A, Wierda W, Shan J, Davis J, Giles F, Saba HI, Issa JP. Kantarjian H, et al. Among authors: oki y. Blood. 2007 Jan 1;109(1):52-7. doi: 10.1182/blood-2006-05-021162. Epub 2006 Aug 1. Blood. 2007. PMID: 16882708 Free article. Clinical Trial.

2

JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia.

Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP. Jelinek J, et al. Among authors: oki y. Blood. 2005 Nov 15;106(10):3370-3. doi: 10.1182/blood-2005-05-1800. Epub 2005 Jul 21. Blood. 2005. PMID: 16037387 Free PMC article.

3

Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center.

Oki Y, Kantarjian HM, Zhou X, Cortes J, Faderl S, Verstovsek S, O'Brien S, Koller C, Beran M, Bekele BN, Pierce S, Thomas D, Ravandi F, Wierda WG, Giles F, Ferrajoli A, Jabbour E, Keating MJ, Bueso-Ramos CE, Estey E, Garcia-Manero G. Oki Y, et al. Blood. 2006 Feb 1;107(3):880-4. doi: 10.1182/blood-2005-06-2450. Epub 2005 Aug 25. Blood. 2006. PMID: 16123215 Free article.

4

Silencing of bidirectional promoters by DNA methylation in tumorigenesis.

Shu J, Jelinek J, Chang H, Shen L, Qin T, Chung W, Oki Y, Issa JP. Shu J, et al. Among authors: oki y. Cancer Res. 2006 May 15;66(10):5077-84. doi: 10.1158/0008-5472.CAN-05-2629. Cancer Res. 2006. PMID: 16707430

5

Mutations and promoter methylation status of NPM1 in myeloproliferative disorders.

Oki Y, Jelinek J, Beran M, Verstovsek S, Kantarjian HM, Issa JP. Oki Y, et al. Haematologica. 2006 Aug;91(8):1147-8. Epub 2006 Jul 25. Haematologica. 2006. PMID: 16870548

6

Decitabine--bedside to bench.

Oki Y, Aoki E, Issa JP. Oki Y, et al. Crit Rev Oncol Hematol. 2007 Feb;61(2):140-52. doi: 10.1016/j.critrevonc.2006.07.010. Epub 2006 Oct 4. Crit Rev Oncol Hematol. 2007. PMID: 17023173 Review.

7

Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.

Oki Y, Kantarjian HM, Gharibyan V, Jones D, O'brien S, Verstovsek S, Cortes J, Morris GM, Garcia-Manero G, Issa JP. Oki Y, et al. Cancer. 2007 Mar 1;109(5):899-906. doi: 10.1002/cncr.22470. Cancer. 2007. PMID: 17236224 Free article. Clinical Trial.

8

A parallel phase I/II clinical trial design for combination therapies.

Huang X, Biswas S, Oki Y, Issa JP, Berry DA. Huang X, et al. Among authors: oki y. Biometrics. 2007 Jun;63(2):429-36. doi: 10.1111/j.1541-0420.2006.00685.x. Biometrics. 2007. PMID: 17688495

9

Treatment options in advanced myelodysplastic syndrome, with emphasis on epigenetic therapy.

Oki Y, Issa JP. Oki Y, et al. Int J Hematol. 2007 Nov;86(4):306-14. doi: 10.1532/IJH97.07034. Int J Hematol. 2007. PMID: 18055336 Review.

10

Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia.

Oki Y, Jelinek J, Shen L, Kantarjian HM, Issa JP. Oki Y, et al. Blood. 2008 Feb 15;111(4):2382-4. doi: 10.1182/blood-2007-07-103960. Epub 2007 Nov 30. Blood. 2008. PMID: 18055864 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

580 results

Search Page

Filters